DRV/r + RPV QD: Efficacy and Toxicity Reduction

NCT01792570 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: RPV + DRV/r
DRUG: continue the PI/r-containing HAART.

Sponsor

ASST Fatebenefratelli Sacco

Collaborators

[object Object]
[object Object]
[object Object]